Amedisys (NASDAQ:AMED) is set to release its earnings data after the market closes on Tuesday, February 27th. Analysts expect Amedisys to post earnings of $0.58 per share for the quarter.
Shares of Amedisys (NASDAQ:AMED) opened at $56.46 on Tuesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.33 and a quick ratio of 1.33. Amedisys has a 1 year low of $45.60 and a 1 year high of $65.91. The stock has a market cap of $1,920.00, a P/E ratio of 44.81, a price-to-earnings-growth ratio of 1.15 and a beta of 0.73.
Several brokerages have issued reports on AMED. BidaskClub raised shares of Amedisys from a “strong sell” rating to a “sell” rating in a research report on Wednesday, February 7th. Zacks Investment Research downgraded shares of Amedisys from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Mizuho reaffirmed a “buy” rating and issued a $65.00 price objective (up previously from $55.00) on shares of Amedisys in a research report on Wednesday, November 8th. Benchmark reaffirmed a “hold” rating on shares of Amedisys in a research report on Thursday, November 9th. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $68.00 price objective (up previously from $55.00) on shares of Amedisys in a research report on Thursday, November 9th. One analyst has rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $60.64.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.